ClinicalTrials.gg
RecruitingNCT07312474ANARETROUpdated Dec 31, 2025

Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace

An observational study in Human Anaplasmosis, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by University Hospital, Strasbourg, France · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Anaplasmosis is a bacterial infection caused by the intracellular bacterium Anaplasma phagocytophilum and transmitted by ticks. This bacterium is present in approximately 1% of ticks in Alsace. This infection is responsible for clinical manifestations that are most often mild, including fever, headache, and myalgia, occurring 2 to 3 weeks after a tick bite. However, this infection can be accompanied by potentially serious or even fatal complications, including severe cytopenias, acute respiratory distress syndrome, septic shock, severe neurological disorders, hemorrhagic manifestations, macrophage activation syndrome, and multiple organ failure. Mortality is variable and appears to be higher in American studies, where it is around 4%. Treatment is well-established and relies on doxycycline, which is highly effective. Although a few cases have been described in France, these are mostly isolated cases or short series of cases, whereas Belgium, Poland, and Slovenia have reported numerous cases. Thus, there is a lack of data on French cases, and given that Alsace is in a region with a high prevalence of tick-borne diseases, data is needed to better understand the epidemiology and to better identify suspected cases in order to provide appropriate care.

02

Conditions studied

  • Human Anaplasmosis

Keywords

  • Human Anaplasmosis
  • Ticks
  • Tick bite
  • Severe cytopenias
  • Respiratory distress syndrome
  • Septic shock
  • Neurological disorders
  • Macrophage activation syndrome
03

In context

Cytopenia

81 studies on the registry are indexed under Cytopenia; 25 are open to participants now.

This study's planned enrollment of 100 is below the median of 202 across 15 observational studies indexed under Cytopenia.

Browse Cytopenia studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Adult subjct (≥18 years) having a PCR-confirmed infection of Anaplasma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjct (≥18 years)
  • Presenting with a PCR-confirmed infection of Anaplasma

Exclusion criteria

Exclusion Criteria:

- Refusal to participate in the study

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Mortality of cases of human anaplasmosis in Alsace

    Time frame: Up to 12 years

07

Study locations

1 of 1 sites recruiting
  • Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
    Strasbourg, 67091, France
    Recruiting
    • Victor Gerber, MD · Contactvictor.gerber@chru-strasbourg.frr · 33 3.88.11.67.68
    • Victor Gerber, MD · Principal investigator
    • Yves Hansmann, MD · Sub investigator
    • Pierre Boyer, PharmD · Sub investigator
    • Thomas Lemmet, MD · Principal investigator
    • Thomas Bonijoly, MD · Principal investigator
    • Baptiste Hoellinger, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Feb 2026, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 31, 2025
StartActual
Oct 2, 2024
Primary completionEst.
Feb 2026
CompletionEst.
Feb 2026
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07312474
Responsible party
Sponsor
First posted
Dec 31, 2025
Start date
Oct 2, 2024
Primary completion
Feb 2026 (estimated)
Completion
Feb 2026 (estimated)
Last update
Dec 31, 2025

Study contacts

Victor GERBER, MD
Contact
victor.gerber@chru-strasbourg.fr
33 3.88.11.67.68

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion